Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, biotech stocks can be highly volatile.However, some exceptions aren't nearly as risky. A few are even practically no-brainer picks for long-term investors. Here's why I think Vertex Pharmaceuticals (VRTX -0.20%) is the ultimate biotech stock to buy with $500 right now.Financially strongMany biotechnology companies don't have approved products on the market, so they don't generate relia ...

Investing can sometimes require a significant amount of upfront cash. For example, you might need a lot of capital to buy real estate properties or launch a new business. However, even individuals without much money can invest in stocks.If you have $500, you should check out Vertex Pharmaceuticals (VRTX -0.19%). Here's why this biotech stock is a great candidate to buy and hold forever.By the numbersLet's talk numbers. First, Vertex's share price currently stands below $450. You could buy one share with $50 ...

Biotech Vertex Pharmaceuticals (VRTX) has been struggling on the charts over the past few weeks, putting a dent in its now 10% year-to-date gain. The stock’s 5.6% post-earnings pop earlier this month has already been erased, and VRTX is now trading at its lowest level since June. The upside is that this extended pullback has the shares encountering a historically bullish area on the charts.The "buy" signal in question is a test of the stock’s bottom 20-day Bollinger Band. After the past eight tests of this ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals. Good to see you again. We had a nice dinner last night. Stuart Arbuckle We did. Question-and-Answer Session Q - Paul Matteis Maybe to start, Stuart, I think we can have ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ET Company Participants Stuart Arbuckle - EVP, COO Conference Call Participants Paul Matteis - Stifel Paul Matteis Great, good morning. It's my pleasure to be moderating this chat with Stuart Arbuckle, COO of Vertex Pharmaceuticals. Good to see you again. We had a nice dinner last night. Stuart Arbuckle We did. Question-and-Answer Session Q - Paul Matteis Maybe to start, Stuart, I think we can have ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 9:00 AM ET Company Participants Reshma Kewalramani - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good morning, and thank you for joining Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit, one of the therapeutic analysts, and my privilege to welcome Dr. Reshma Kewalramani, President and CEO of Vertex. T ...

Regulators are reviewing what could become a multi-billion-dollar drug. Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals (VRTX -2.34%) has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company's portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue -- in the most recent q ...

Vertex Pharmaceuticals (VRTX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VRTX broke through the 20-day moving average, which suggests a short-term bullish trend.The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages ...

From a technical perspective, Vertex Pharmaceuticals (VRTX) is looking like an interesting pick, as it just reached a key level of support. VRTX recently overtook the 50-day moving average, and this suggests a short-term bullish trend.The 50-day simple moving average, which is one of three major moving averages, is widely used by traders and analysts to establish support and resistance levels for a range of securities. Because it's the first sign of an up or down trend, the 50-day is considered to be more i ...

Vertex Pharmaceuticals (VRTX) reported $2.77 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 11.6%. EPS of $4.38 for the same period compares to $4.08 a year ago.The reported revenue represents a surprise of +3.62% over the Zacks Consensus Estimate of $2.67 billion. With the consensus EPS estimate being $4.13, the EPS surprise was +6.05%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...